Codiak BioSciences, Inc.

2022 Q4 Form 10-Q Financial Statement

#000095017022021879 Filed on November 03, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $51.76M $98.58M
YoY Change -47.49% 104.11%
Cash & Equivalents $51.76M $98.58M
Short-Term Investments
Other Short-Term Assets $9.471M $5.329M
YoY Change 77.73% 29.98%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $61.23M $103.9M
YoY Change -41.07% 98.45%
LONG-TERM ASSETS
Property, Plant & Equipment $20.54M $29.38M
YoY Change -30.1% -6.85%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $31.67M $4.170M
YoY Change 659.47% 8240.0%
Total Long-Term Assets $73.16M $54.81M
YoY Change 33.48% -5.48%
TOTAL ASSETS
Total Short-Term Assets $61.23M $103.9M
Total Long-Term Assets $73.16M $54.81M
Total Assets $134.4M $158.7M
YoY Change -15.33% 43.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.956M $1.998M
YoY Change -2.1% -19.69%
Accrued Expenses $8.126M $9.315M
YoY Change -12.76% -60.96%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $14.46M $23.10M
YoY Change -37.43% -32.82%
LONG-TERM LIABILITIES
Long-Term Debt $25.69M $25.35M
YoY Change 1.35% 2.23%
Other Long-Term Liabilities $55.32M $76.26M
YoY Change -27.47% -19.89%
Total Long-Term Liabilities $81.01M $101.6M
YoY Change -20.28% -15.32%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.46M $23.10M
Total Long-Term Liabilities $81.01M $101.6M
Total Liabilities $95.47M $124.7M
YoY Change -23.45% -19.22%
SHAREHOLDERS EQUITY
Retained Earnings -$359.3M -$341.9M
YoY Change 5.09% 26.57%
Common Stock $4.000K $2.000K
YoY Change 100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares $0.00 $0.00
Shareholders Equity $38.93M $34.01M
YoY Change
Total Liabilities & Shareholders Equity $134.4M $158.7M
YoY Change -15.33% 43.84%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001659352
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39615
dei Entity Registrant Name
EntityRegistrantName
CODIAK BIOSCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-4926530
us-gaap Sublease Income
SubleaseIncome
1188000
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Address Address Line1
EntityAddressAddressLine1
35 CambridgePark Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 500
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02140
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
949-4100
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
CDAK
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
36829626
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51762000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
76938000
CY2022Q3 cdak Prepaid Manufacturing Services Current
PrepaidManufacturingServicesCurrent
6727000
CY2021Q4 cdak Prepaid Manufacturing Services Current
PrepaidManufacturingServicesCurrent
7315000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2744000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5918000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
61233000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
90171000
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
14990000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11809000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20538000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23479000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
4170000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
4170000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20955000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
21957000
CY2022Q3 cdak Prepaid Manufacturing Services Noncurrent
PrepaidManufacturingServicesNoncurrent
27500000
CY2021Q4 cdak Prepaid Manufacturing Services Noncurrent
PrepaidManufacturingServicesNoncurrent
31893000
CY2022Q3 us-gaap Assets
Assets
134396000
CY2021Q4 us-gaap Assets
Assets
171670000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1956000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1838000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8126000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9703000
CY2022Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1363000
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
12963000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3011000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2661000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
14456000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
27165000
CY2022Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
17317000
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
30686000
CY2022Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
25693000
CY2021Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
25430000
CY2022Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
5428000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
32573000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
34884000
CY2022Q3 us-gaap Liabilities
Liabilities
95467000
CY2021Q4 us-gaap Liabilities
Liabilities
118165000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36829626
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36829626
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22383830
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22383830
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
4000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
398253000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
378750000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-359328000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-325247000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
38929000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
53505000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
134396000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
171670000
CY2022Q3 us-gaap Revenues
Revenues
522000
CY2021Q3 us-gaap Revenues
Revenues
1157000
us-gaap Revenues
Revenues
26371000
us-gaap Revenues
Revenues
15238000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10847000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15467000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
37893000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
47436000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6563000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7186000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20634000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20711000
CY2022Q3 cdak Impairment Of Prepaid Manufacturing Services
ImpairmentOfPrepaidManufacturingServices
4508000
cdak Impairment Of Prepaid Manufacturing Services
ImpairmentOfPrepaidManufacturingServices
4508000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
21918000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
22653000
us-gaap Operating Expenses
OperatingExpenses
63035000
us-gaap Operating Expenses
OperatingExpenses
68147000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-21396000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-21496000
us-gaap Operating Income Loss
OperatingIncomeLoss
-36664000
us-gaap Operating Income Loss
OperatingIncomeLoss
-52909000
CY2022Q3 us-gaap Interest Expense
InterestExpense
758000
CY2021Q3 us-gaap Interest Expense
InterestExpense
689000
us-gaap Interest Expense
InterestExpense
2007000
us-gaap Interest Expense
InterestExpense
2091000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
119000
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
4000
us-gaap Investment Income Interest
InvestmentIncomeInterest
157000
us-gaap Investment Income Interest
InvestmentIncomeInterest
18000
CY2022Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
35000
CY2021Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
479000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1711000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1163000
CY2022Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2722000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2722000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2118000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-206000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2583000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-910000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-19278000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-21702000
us-gaap Net Income Loss
NetIncomeLoss
-34081000
us-gaap Net Income Loss
NetIncomeLoss
-53819000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.77
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.77
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.97
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.97
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.46
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.46
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.49
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.49
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25159757
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25159757
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22325334
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22325334
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23373684
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23373684
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21599405
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21599405
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
53505000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2349000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-8028000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
48379000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
126000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2668000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-6775000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
44398000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2287000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
491000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-19278000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
38929000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
14567000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
316000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2273000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-10308000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
68716000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2454000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2690000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
187000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-21809000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
51864000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
752000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3092000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-21702000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
34006000
us-gaap Profit Loss
ProfitLoss
-34081000
us-gaap Profit Loss
ProfitLoss
-53819000
us-gaap Share Based Compensation
ShareBasedCompensation
7304000
us-gaap Share Based Compensation
ShareBasedCompensation
8055000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2722000
cdak Impairment Of Prepaid Manufacturing Services
ImpairmentOfPrepaidManufacturingServices
4508000
us-gaap Paid In Kind Interest
PaidInKindInterest
308000
us-gaap Paid In Kind Interest
PaidInKindInterest
392000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3181000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4205000
cdak Non Cash Manufacturing Expense1
NonCashManufacturingExpense1
462000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2949000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
651000
cdak Increase Decrease In Prepaid Manufacturing Services
IncreaseDecreaseInPrepaidManufacturingServices
-12000
cdak Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-1003000
cdak Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-745000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
175000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
206000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1725000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1118000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-24970000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-11953000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1962000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-920000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-45558000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-52622000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
362000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2913000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-362000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2913000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3523000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
126000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
20618000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
61681000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20744000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
65204000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-25176000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9669000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
81108000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
93085000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
55932000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
102754000
us-gaap Interest Paid Net
InterestPaidNet
1696000
us-gaap Interest Paid Net
InterestPaidNet
1713000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
28000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
388000
cdak Offering Costs Included In Accrued Expenses
OfferingCostsIncludedInAccruedExpenses
267000
cdak Issuance Of Derivative Liability Warrants
IssuanceOfDerivativeLiabilityWarrants
8150000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51762000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
98584000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
4170000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
4170000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
55932000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
102754000
us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1. Nature of the Business</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Codiak BioSciences, Inc. (collectively, with its consolidated subsidiaries, any of "Codiak", "we", "us", or the "Company") was incorporated in Delaware on </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">June 12, 2015</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> and is headquartered in Cambridge, Massachusetts. Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. Exosomes have evolved as intercellular transfer mechanisms for complex, biologically active macromolecules and have emerged in recent years as a compelling potential drug delivery vehicle. By leveraging its deep understanding of exosome biology, the Company has developed its engineering and manufacturing platform (the "engEx Platform"), to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutics. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes ("engEx exosomes") aimed at treating a broad range of diseases, including oncology, and infectious disease and rare disease. In </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">September 2020, Codiak initiated clinical trials for two of its lead product candidates, exoSTING and exoIL-12, which were being developed to address oncology indications. In June 2022, the Company initiated a Phase 1 clinical trial of exoASO-STAT6, Codiak’s first systemically delivered exosome therapeutic candidate. In August 2022, the Company paused clinical trials for exoSTING and exoIL-12 to prioritize focus on its Phase 1 clinical trial for exoASO-STAT6 (see Note 13).To the Company's knowledge, exoSTING and exoIL-12 are the first engineered exosomes to enter clinical development.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Since its inception, the Company has devoted substantially all of its resources to its research and development efforts, including activities to develop its engEx Platform, advance engEx product candidates into clinical trials, perform preclinical research to identify potential engEx product candidates, perform process development to refine Codiak’s exosome engineering and manufacturing processes, and provide general and administrative support for these operations.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company has primarily funded its operations with proceeds from the sales of common stock, redeemable convertible preferred stock, collaborative and research arrangements with Jazz Pharmaceuticals Ireland Limited ("Jazz") and Sarepta Therapeutics, Inc. ("Sarepta") and its loan and security agreement with Hercules Capital, Inc. ("Hercules"). As of September 30, 2022, the Company has raised an aggregate of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">168.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million through the issuance of its redeemable convertible preferred stock and convertible debt, net of issuance costs, $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">24.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million from its term loan facility with Hercules, net of issuance costs, and received $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">66.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million in payments from its collaborations with Jazz and Sarepta. On </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">October 16, 2020, the Company completed its initial public offering ("IPO"), pursuant to which it issued and sold </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5,500,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of its common stock at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">15.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> per share, resulting in net proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">74.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and other offering expenses. On February 17, 2021, the Company completed a follow-on public offering, pursuant to which it issued </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3,162,500</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of its common stock (inclusive of the exercise of the underwriter’s option to purchase </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">412,500</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> additional shares of common stock) at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">21.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> per share, resulting in aggregate net proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">61.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and other offering expenses. On September 15, 2022, the Company completed a follow-on public offering, pursuant to which it issued </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">14,027,665</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of its common stock and accompanying warrants to purchase </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">14,027,665</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of its common stock (inclusive of the partial exercise of the underwriter’s option to purchase </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">694,332</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> additional shares of common stock and accompanying warrants to purchase </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">694,332</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> additional shares of common stock) at a combined public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1.50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> per share, resulting in aggregate net proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">19.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and other offering expenses. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">During the nine-month period ended September 30, 2022, the Company raised $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million utilizing an "at-the-market" offering facility, pursuant to which it sold </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">236,303</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of its common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company has incurred significant operating losses and negative cash flows from operations since inception and expects to continue to incur operating losses for the foreseeable future. In addition, the Company anticipates that its expenses will increase significantly in connection with ongoing activities to support its engEx Platform development, drug discovery and preclinical and clinical development, in addition to creating a portfolio of intellectual property and providing administrative support.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company does not expect to generate significant revenue from sales of its engEx product candidates unless and until clinical development has been successfully completed and regulatory approval is obtained. If the Company obtains regulatory approval for any of its investigational products, it expects to incur significant commercialization expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">one year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> after the date that the consolidated financial statements are issued.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> The Company expects that its cash and cash equival</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ents of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">51.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million as of September</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> 30, 2022 will be insufficient to allow the Company to fund its current operating plan through at least the next 12 months from the issuance of these financial statements. Maintaining the Company's ongoing operations is dependent upon its ability to obtain additional financing, as to which it can make no assurance. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of at least one year from the date these financial statements are issued. Accordingly, the Company will be required to raise additional funds through an additional public equity financing, establish collaborations with or license its technology to other companies, or seek alternative means of financial support in order to continue to fund its operations in the future. There can be no assurance, however, that additional fundraising will be successful and available on terms acceptable to the Company, or at all. If the Company is unable to raise capital when needed or on attractive terms, it may be forced to delay, reduce, or eliminate certain costs related to its operations and research and development programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company is subject to those risks associated with any biopharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants. If the Company fails to become profitable or is unable to sustain profitability on a continuing basis, then it may be unable to continue its operations at planned levels and be forced to reduce its operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2015-06-12
us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
168200000
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
24600000
us-gaap Proceeds From Collaborators
ProceedsFromCollaborators
66000000.0
CY2020Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5500000
CY2020Q4 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
15.00
CY2020Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
74400000
CY2021Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3162500
CY2021Q1 cdak Additional Stock Issued During Period Shares New Issues
AdditionalStockIssuedDuringPeriodSharesNewIssues
412500
CY2021Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
21.00
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
61700000
CY2022Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
14027665
CY2022Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
14027665
CY2022Q3 cdak Additional Stock Issued During Period Shares New Issues
AdditionalStockIssuedDuringPeriodSharesNewIssues
694332
CY2022Q3 cdak Additional Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
AdditionalClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
694332
CY2022Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
1.50
CY2022Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
19800000
us-gaap Substantial Doubt About Going Concern Conditions Or Events
SubstantialDoubtAboutGoingConcernConditionsOrEvents
The Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.
us-gaap Substantial Doubt About Going Concern Within One Year
SubstantialDoubtAboutGoingConcernWithinOneYear
true
CY2022Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
51800000
CY2022Q3 us-gaap Lease Cost
LeaseCost
1527000
CY2021Q3 us-gaap Lease Cost
LeaseCost
1370000
us-gaap Lease Cost
LeaseCost
3656000
us-gaap Lease Cost
LeaseCost
4356000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have made estimates and judgments affecting the amounts reported in our consolidated financial statements and the accompanying notes. On an ongoing basis, we evaluate our estimates, including critical accounting policies or estimates related to revenue recognition, stock-based compensation, accrued expenses, leases, gain upon derecognition, contingent consideration, prepaid manufacturing services, warrants and impairment assessments. We base our estimates on historical experience and various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. The actual results that we experience may differ materially from our estimates.</span></p>
CY2021Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
8000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
12000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
21000
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
712000
CY2021Q3 us-gaap Variable Lease Cost
VariableLeaseCost
638000
us-gaap Variable Lease Cost
VariableLeaseCost
2026000
us-gaap Variable Lease Cost
VariableLeaseCost
1897000
CY2022Q3 us-gaap Sublease Income
SubleaseIncome
430000
CY2021Q3 us-gaap Sublease Income
SubleaseIncome
484000
us-gaap Sublease Income
SubleaseIncome
2102000
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4266000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5142000
CY2022Q3 cdak Accrued External Research And Development Cost Current
AccruedExternalResearchAndDevelopmentCostCurrent
2045000
CY2021Q4 cdak Accrued External Research And Development Cost Current
AccruedExternalResearchAndDevelopmentCostCurrent
2420000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1201000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1523000
CY2022Q3 us-gaap Accrued Utilities Current
AccruedUtilitiesCurrent
263000
CY2021Q4 us-gaap Accrued Utilities Current
AccruedUtilitiesCurrent
190000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
351000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
428000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8126000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9703000
cdak Lease Expiration Year
LeaseExpirationYear
2029
cdak Number Of Location
NumberOfLocation
2
CY2022Q3 us-gaap Sublease Income
SubleaseIncome
400000
us-gaap Sublease Income
SubleaseIncome
2100000
CY2021Q3 us-gaap Sublease Income
SubleaseIncome
500000
us-gaap Sublease Income
SubleaseIncome
1200000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1240000
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1208000
us-gaap Operating Lease Cost
OperatingLeaseCost
3720000
us-gaap Operating Lease Cost
OperatingLeaseCost
3626000
CY2022Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
5000
us-gaap Operating Lease Payments
OperatingLeasePayments
4700000
us-gaap Operating Lease Payments
OperatingLeasePayments
4500000
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y2M12D
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y2M12D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.101
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.103
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1573000
CY2022Q3 cdak Lessee Operating Sublease Payments To Be Received Remainder Of Fiscal Year
LesseeOperatingSubleasePaymentsToBeReceivedRemainderOfFiscalYear
250000
CY2022Q3 cdak Lessee Net Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeNetOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1323000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
6436000
CY2022Q3 cdak Lessee Operating Sublease Payments To Be Received Next Twelve Months
LesseeOperatingSubleasePaymentsToBeReceivedNextTwelveMonths
1024000
CY2022Q3 cdak Lessee Net Operating Lease Liability Payments Due Next Twelve Months
LesseeNetOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
5412000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
6625000
CY2022Q3 cdak Lessee Operating Sublease Payments To Be Received Two Years
LesseeOperatingSubleasePaymentsToBeReceivedTwoYears
965000
CY2022Q3 cdak Lessee Net Operating Lease Liability Payments Due Year Two
LesseeNetOperatingLeaseLiabilityPaymentsDueYearTwo
5660000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
6820000
CY2022Q3 cdak Lessee Net Operating Lease Liability Payments Due Year Three
LesseeNetOperatingLeaseLiabilityPaymentsDueYearThree
6820000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
7020000
CY2022Q3 cdak Lessee Net Operating Lease Liability Payments Due Year Four
LesseeNetOperatingLeaseLiabilityPaymentsDueYearFour
7020000
CY2022Q3 cdak Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
21779000
CY2022Q3 cdak Lessee Net Operating Lease Liability Payments Due After Year Four
LesseeNetOperatingLeaseLiabilityPaymentsDueAfterYearFour
21779000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
50253000
CY2022Q3 cdak Lessee Operating Sublease Payments To Be Received
LesseeOperatingSubleasePaymentsToBeReceived
2239000
CY2022Q3 cdak Lessee Net Operating Lease Liability Payments Due
LesseeNetOperatingLeaseLiabilityPaymentsDue
48014000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
14669000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
35584000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y3M18D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2022Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
208680
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
834720
CY2020Q4 cdak Annual Increased Percentage On Outstanding Common Stock Reserved
AnnualIncreasedPercentageOnOutstandingCommonStockReserved
0.005
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4763489
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.56
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y5M8D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
10370000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1253675
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.74
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
796424
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
13.44
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5220740
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.79
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y11M23D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3166270
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
10.08
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y6M10D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5220740
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
10.79
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y11M23D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0.0
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
800000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0.0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
5100000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2287000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3092000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7304000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8055000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2287000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3092000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7304000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8055000
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
16400000
CY2021Q4 cdak Contract With Customer Asset Accounts Receivable
ContractWithCustomerAssetAccountsReceivable
628000
cdak Contract With Customer Asset Accounts Receivable Deductions
ContractWithCustomerAssetAccountsReceivableDeductions
628000
CY2021Q4 cdak Contract With Customer Liability Deferred Revenue
ContractWithCustomerLiabilityDeferredRevenue
43649000
cdak Contract With Customer Liability Deferred Revenue Deductions
ContractWithCustomerLiabilityDeferredRevenueDeductions
26044000
CY2022Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
17605000
CY2022Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
28000
CY2021Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1157000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
26044000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
15238000
CY2022Q3 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.37
CY2022Q3 us-gaap Restructuring Charges
RestructuringCharges
700000
us-gaap Restructuring Charges
RestructuringCharges
700000
CY2022Q3 cdak Non Cash Stock Based Compensation Expense
NonCashStockBasedCompensationExpense
200000
cdak Non Cash Stock Based Compensation Expense
NonCashStockBasedCompensationExpense
200000
us-gaap Restructuring Charges
RestructuringCharges
651000
us-gaap Payments For Restructuring
PaymentsForRestructuring
329000
cdak Restructuring Reserve Sock Based Compensation Expense
RestructuringReserveSockBasedCompensationExpense
-151000
CY2022Q3 us-gaap Restructuring Reserve
RestructuringReserve
171000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-19278000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-21702000
us-gaap Net Income Loss
NetIncomeLoss
-34081000
us-gaap Net Income Loss
NetIncomeLoss
-53819000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19278000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21702000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-34081000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-53819000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25159757
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25159757
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22325334
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22325334
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23373684
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23373684
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21599405
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21599405
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.77
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.77
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.97
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.97
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.46
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.46
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.49
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.49
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20852516
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4953272
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20852516
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4953272

Files In Submission

Name View Source Status
0000950170-22-021879-index-headers.html Edgar Link pending
0000950170-22-021879-index.html Edgar Link pending
0000950170-22-021879.txt Edgar Link pending
0000950170-22-021879-xbrl.zip Edgar Link pending
cdak-20220930.htm Edgar Link pending
cdak-20220930.xsd Edgar Link pending
cdak-ex31_1.htm Edgar Link pending
cdak-ex31_2.htm Edgar Link pending
cdak-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
cdak-20220930_cal.xml Edgar Link unprocessable
cdak-20220930_def.xml Edgar Link unprocessable
cdak-20220930_pre.xml Edgar Link unprocessable
cdak-20220930_lab.xml Edgar Link unprocessable
cdak-20220930_htm.xml Edgar Link completed
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending